Terminal Patient Access & Quality Care
-
Author:
n/a -
Send To:
Senator Feinstein and all other elected officials concerned
-
Sponsored By:
-
More Info at:
Senator Feinstein,
In recognizing
an estimated 80\% of clinical trials are delayed in the United States due to inadequate enrollment
an anemic 3\% to 5\% of all adult cancer patients ever join clinical trials
approximately 8 years pass from the time a cancer therapy enters clinical trials to the time it receives FDA approval for sale to the public, on top of the six years of research spent before it enters clinical study
thousands of terminal patients continue living today unaware of their option to utilize experimental therapies outside of a clinical trial (I.e, Expanded Access programs)
only approximately 11 open Expanded Access programs for cancer exist while approximately 6,700 open clinical trials for cancer exist (about 1/100th of ONE PERCENT of therapies in clinical trial for cancer are also available for Expanded Access)
thousands of illnesses can be better combated if done so through drug cocktails rather than through attacking these ailments one mechanism of action at a time
there is significant benefit to patients of whom are seriously ill to undergo molecular and genetic diagnostic methods to more effectively be treated
We petition that you spend your valuable time to solve these problems and accomplish the following goals, recognizing them as most important to us:
1. To increase and improve terminal and seriously ill patients' access to experimental therapies, and their knowledge of this access.
2. To improve enrollment in clinical trials.
3. To increase the utilization of personalized diagnosis and treatment, most especially in the event of serious or terminal illness.
4. To stimulate the amount of drug cocktails investigated for various diseases and ailments.
5. To review the FDA goals regarding drug approval to ensure they are in the best interest of patients, that interest being to have the most effective and safe medical care possible.
We urge you to take immediate action to solve these issues, and we strongly request that a detailed proposal to solve these issues is written, completed, and set for implementation within the remainder of the year. We implore you to include Ryan Joseph Witt in this process to ensure that our needs are met. Inaction is not an option. We will follow up on your progress. Thank you.
In recognizing
an estimated 80\% of clinical trials are delayed in the United States due to inadequate enrollment
an anemic 3\% to 5\% of all adult cancer patients ever join clinical trials
approximately 8 years pass from the time a cancer therapy enters clinical trials to the time it receives FDA approval for sale to the public, on top of the six years of research spent before it enters clinical study
thousands of terminal patients continue living today unaware of their option to utilize experimental therapies outside of a clinical trial (I.e, Expanded Access programs)
only approximately 11 open Expanded Access programs for cancer exist while approximately 6,700 open clinical trials for cancer exist (about 1/100th of ONE PERCENT of therapies in clinical trial for cancer are also available for Expanded Access)
thousands of illnesses can be better combated if done so through drug cocktails rather than through attacking these ailments one mechanism of action at a time
there is significant benefit to patients of whom are seriously ill to undergo molecular and genetic diagnostic methods to more effectively be treated
We petition that you spend your valuable time to solve these problems and accomplish the following goals, recognizing them as most important to us:
1. To increase and improve terminal and seriously ill patients' access to experimental therapies, and their knowledge of this access.
2. To improve enrollment in clinical trials.
3. To increase the utilization of personalized diagnosis and treatment, most especially in the event of serious or terminal illness.
4. To stimulate the amount of drug cocktails investigated for various diseases and ailments.
5. To review the FDA goals regarding drug approval to ensure they are in the best interest of patients, that interest being to have the most effective and safe medical care possible.
We urge you to take immediate action to solve these issues, and we strongly request that a detailed proposal to solve these issues is written, completed, and set for implementation within the remainder of the year. We implore you to include Ryan Joseph Witt in this process to ensure that our needs are met. Inaction is not an option. We will follow up on your progress. Thank you.
-
28
Signatures! - View Signatures
- Sign Petition